Background The metabolic basis of Alzheimer disease (AD) pathology and expression of AD
symptoms is poorly understood. Omega-3 and-6 fatty acids have previously been linked to …

Plasma fatty acids have been reported to be dysregulated in mild cognitive impairment (MCI)
and Alzheimer's disease (AD), though outcomes are not always consistent, and subject …

Alzheimer's disease (AD) is generally associated with lower omega-3 fatty acid intake from
fish but despite numerous studies, it is still unclear whether there are differences in omega-3 …

The development of Alzheimer's dementia (AD) accompanies both central and peripheral
metabolic disturbance, but the metabolic basis underlying AD and metabolic markers …

The molecular bases of Alzheimer's disease (AD) remain unclear. We used a lipidomic
approach to identify lipid abnormalities in the brains of subjects with AD (N= 37) compared …

Previous studies showed the relationship between fatty acids and the risk of developing
Alzheimer's disease (AD). However, they did not address potential differences in free fatty …

Dietary ω3-polyunsaturated fatty acids are thought to influence the risk of Alzheimer's
disease (AD), and supplemental docosahexaenoic acid (DHA; 22: 6n-3) has been reported …

Background Previous clinical and animal studies suggested that medium-chain triglycerides
(MCT) might be an alternative energy substrate for the brain and might benefit patients with …

Objective: The long-chain ω-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) are potential candidates for interventions to delay Alzheimer …

Background Although saturated (SAFA), monounsaturated (MUFA), and polyunsaturated
(PUFA) fatty acids are important structural components of neuronal membranes and …